Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Frank A. Holler

Corporate Director

Frank A. Holler

Frank A. Holler is currently President & CEO of Ponderosa Capital Inc. He previously served as Chairman & CEO of BC Advantage Funds (VCC) Ltd., a venture capital firm investing in emerging technology companies in British Columbia.

He also served as President and CEO of Xenon Pharmaceuticals Inc. from 1999 to 2003 after having been President and CEO of ID Biomedical Corporation from 1991 to 1998. In addition, he was a founding director of Angiotech Pharmaceuticals.

Prior to working in biotechnology and healthcare, Mr. Holler was a Vice-President of Investment Banking with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets). 

Mr. Holler holds an MBA and BA (Economics) from the University of British Columbia.

    Headquarters

    Theratechnologies inc.
    2015 Peel Street, 11th Floor
    Montréal, Québec
    Canada H3A 1T8
    Phone: 514 336-7800
    Fax: 514 331-9691

    European Headquarters

    Theratechnologies Europe Limited
    2 Hume Street, 4th floor
    Dublin 2
    Ireland D02 DV24
    Phone: +353 1 215 0650
    europe@theratech.com

    Investor Relations

    Elif McDonald
    Senior Director, Investor Relations
    Phone: +1-438-315-8563
    ir@theratech.com

    US Headquarters

    Theratechnologies U.S., Inc.
    101 Hudson Street
    21st Floor
    Jersey City, New Jersey 07302

    Main Nav

    • Home
    • About
    • Medicines & Pipeline
    • Investors
    • Corporate Responsibility
    • Careers
    • Contact Us
    ©2023 - Theratechnologies Inc.

    Legal Nav

    • Terms of Use
    • Privacy

    Search

    Theratechnologies